GlobeNewswire Inc | Feb 24, 2021 07:30AM EST

February 24, 2021

WILMETTE, Ill., Feb. 24, 2021 (GLOBE NEWSWIRE) -- MonoparTherapeutics Inc. (Nasdaq: MNPR),a clinical-stagebiopharmaceuticalcompany primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients,todayannounced that Chandler D. Robinson, MD, Chief Executive Officer, is planning to present a Company overview at the following investor conferences in March:

H.C. Wainwright Global Life Sciences ConferenceThe Companys presentation will be webcast on Tuesday, March 9, 2021 at 7:00 a.m. ET

33rd Annual Roth Conference, Healthcare The Companys fireside chat will be webcast on Tuesday, March 16, 2021 at 12:00 p.m. ET

Maxims 2021 Emerging Growth Virtual Conference Presentation time to be determined on Wednesday, March 17, 2021

AboutMonoparTherapeuticsInc.MonoparTherapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopars pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; and a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19. For more information, visit: www.monopartx.com.

CONTACT:

Monopar Therapeutics Inc:Investor RelationsKim R. TsuchimotoChief Financial Officerkimtsu@monopartx.com

Follow Monopar on social media for updates:

Twitter:@MonoparTx LinkedIn:Monopar Therapeutics